Skip to main content

Table 4 Stratified analysis adjusted mortality

From: Association between β-blocker use and mortality in critically ill patients: a nested cohort study

 

180 Day Mortality

ICU Mortality

Hospital Mortality

Variable

N

aOR

95% CI

P value

for interaction

N

aOR

95% CI

P value

for interaction

N

aOR

95% CI

P value

for interaction

Age (years)

Age < 58

230

0.57

0.10–3.2

0.58

263

1.89

0.56–6.4

0.43

263

1.21

0.41–3.5

0.27

Age >  58

247

0.83

0.43–1.62

260

1.48

0.72–3.1

260

1.11

0.62–1.99

Gender

Male

355

0.54

0.23–1.26

0.57

391

1.72

0.80–3.68

0.14

391

0.95

0.49–1.85

0.82

Female

122

1.45

0.52–4.1

132

1.30

0.44–3.88

132

1.45

0.62–3.39

Diabetes

Yes

194

0.63

0.30–1.36

0.07

208

0.93

0.40–2.17

0.01

208

0.73

0.39–1.38

0.002

No

283

1.22

0.40–3.7

315

2.93

1.19–7.23

315

2.43

1.05–5.64

Vasopressors

Yes

307

0.70

0.32–1.50

0.36

341

1.86

0.89–3.89

0.85

341

1.25

0.67–2.32

0.84

No

170

1.10

0.32–3.74

182

0.89

0.27–2.99

182

0.83

0.32–2.18

APACHE II score

<  23

236

0.85

0.22–3.26

0.32

271

2.22

0.66–7.48

0.12

271

1.12

0.40–3.13

0.23

>  23

241

0.67

0.32–1.40

252

1.23

0.59–2.56

252

0.98

0.53–1.82

Sepsis

Yes

117

0.83

0.24–2.95

0.37

122

1.06

0.30–3.78

0.12

122

0.92

0.32–2.63

0.06

No

360

0.71

0.33–1.51

401

1.91

0.90–4.08

401

1.26

0.70–2.37

Severe sepsis

Yes

115

0.52

0.11–2.41

0.71

125

0.73

0.25–2.09

0.19

125

0.71

0.25–2.01

0.72

No

362

0.80

0.39–1.62

398

2.09

092–4.73

398

1.10

0.59–2.06

Admission category

Non-operative

404

0.79

0.41–1.52

0.92

435

1.50

0.78–2.90

0.50

435

1.15

0.67–1.98

0.81

Post-operative

73

0.21

0.015–3.0

88

1.96

0.26–14.71

88

0.52

0.09–3.06

Chronic Respiratory Disease

Yes

68

1.15

0.21–6.32

0.85

70

4.89

1.18–20.30

0.11

70

7.27

1.39–37.93

0.06

No

409

0.62

0.30, 1.26

453

1.28

0.61–2.71

453

0.80

0.44–1.43

Chronic Renal disease

Yes

53

1.22

0.33–4.5

0.97

55

1.39

0.29–6.63

0.69

55

0.82

0.24–2.77

0.25

No

424

0.60

0.28–1.27

468

1.55

0.78–3.09

468

1.10

0.62–1.96

Chronic Cardiac disease

Yes

74

0.56

0.18–1.71

0.13

77

0.69

0.19–2.48

0.09

77

0.45

0.16–1.29

0.003

No

403

0.75

0.34–1.64

446

1.88

0.92–3.85

446

1.34

0.74–2.44

Estimated GFR (mL/min)

≤ 73

246

0.82

0.42–1.62

0.23

261

1.02

0.50–2.05

0.08

261

0.84

0.47–1.50

0.06

> 73

231

0.21

0.03–1.54

262

3.40

0.89–12.89

262

1.36

0.44–4.25

SOFA score

≤ 9

274

0.70

0.26–1.84

0.56

305

1.39

0.51–3.79

0.99

305

0.89

0.40–1.97

0.90

>  9

203

0.77

0.31–1.85

218

1.62

0.71–3.68

218

1.29

0.61–2.73

ICU duration (days)

≤ 5

231

0.74

0.28–1.92

0.70

256

1.44

0.52–4.03

0.51

256

1.07

0.46–2.47

0.31

>  5

246

0.70

0.29–1.71

267

1.60

0.71–3.58

267

1.06

0.50–2.25

Statin Use

Yes

66

0.92

0.30–2.79

0.86

68

0.46

0.10–2.10

0.02

68

1.005

0.35–2.92

0.19

No

411

0.65

0.28–1.51

455

2.29

1.16–4.54

455

1.40

0.76–2.57

  1. aOR adjusted odds ratio, APACHE Acute Physiology and Chronic Health Evaluation, CI confidence interval, GFR glomerular filtration rate, ICU intensive care unit, SOFA Sequential Organ Failure Assessment